Who is sponsoring NCT06786468?

NCT06786468 is sponsored by Mahidol University.

What drugs are being tested in NCT06786468?

Interventions in NCT06786468: Early palliative care integration, Standard systemic treatment for advanced lung cancer.

What condition does NCT06786468 study?

NCT06786468 studies Lung Cancer - Non Small Cell, Lung Cancer (NSCLC).

Is NCT06786468 still recruiting?

NCT06786468 is currently recruiting now. Last updated 20 January 2025.

Last reviewed 2025-01-20 · How we verify

NCT06786468

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Controlled Trial of Standard Care With or Without Early Palliative Care Provided by Palliative Care Specialist in Advanced Non-small Cell Lung Cancer Patients

Recruiting now NA Last updated 20 January 2025

What this trial tests

NA trial testing Early palliative care integration in Lung Cancer - Non Small Cell in 104 participants. Currently enrolling.

Timeline

2 April 2024

Primary endpoint
1 April 2026

1 April 2027

Quick facts

Lead sponsor	Mahidol University
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	104
Start date	2 April 2024
Primary completion	1 April 2026
Estimated completion	1 April 2027
Sites	1 location across Thailand

Drugs / interventions tested

Early palliative care integration — full drug profile →
Standard systemic treatment for advanced lung cancer — full drug profile →

Conditions studied

Lung Cancer - Non Small Cell — all drugs for Lung Cancer - Non Small Cell →
Lung Cancer (NSCLC) — all drugs for Lung Cancer (NSCLC) →

Sponsor

Mahidol University

Who can join

18 and older, any sex, with Lung Cancer - Non Small Cell or Lung Cancer (NSCLC). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Quality of life score (FACT-L Total Score)
Time frame: 12 weeks after treatment
The patients were asked to assess their Health-related Quality Of Life (HRQoL) using FACT-L (Functional Assessment of Cancer Therapy - Lung) questionnaire. The score ranges from 0-136 with higher score indicating better HRQoL.

Sponsor's own description

Early palliative care has been shown to improve the survival of advanced lung cancer patients. However, most of the clinical studies were performed in the era when systemic treatment options for this disease were limited. Currently, many effective treatment options are available, including targeted therapy and immunotherapy. These novel agents improve the treatment outcomes while having less toxicity compared to conventional chemotherapy. Moreover, medical oncologists are now trained to provide palliative care for patients. This study was designed to demonstrate whether early palliative care provided by the palliative care specialist still improves the quality of life or survival of advanced lung cancer patients compared to standard care provided by the medical oncologist.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Early palliative care integration

Trials testing the same drug.

NCT06848270 — Effectiveness of Early Intervention in Palliative Care for Acute Myeloid Leukemia Patients Comparing to Standard of Care · NA · not yet recruiting
NCT03800095 — Early Palliative Care for Patients With Haematological Malignancies · Phase 3 · unknown
NCT06726317 — Early Palliative Care For Patients With Oral Cancer in Sri Lanka · NA · completed

Other recruiting trials for Lung Cancer - Non Small Cell

Currently open trials in the same condition.

NCT06926790 — Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3) · Phase 2 · recruiting
NCT06889467 — Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer · recruiting
NCT06659458 — Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients · recruiting

Other Mahidol University trials

Trials by the same sponsor.

NCT07568496 — Greater Occipital Nerve Block for Migraine With Medication Overuse Headache · NA · not yet recruiting
NCT07407400 — Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients · Phase 4 · not yet recruiting
NCT07378501 — Thai Version of the Pediatric Quality of Recovery Score (PedSQoR): Translation and Psychometric Validation Study · not yet recruiting
NCT07438301 — Septic Shock Hemodynamic Respond to Volume Resuscitation Versus Vasopressor Administration · not yet recruiting
NCT07390006 — Enabling Patient-Reported Outcomes Through Innovative Care - ACS (EPIC-ACS) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06786468 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mahidol University
Last refreshed: 20 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06786468.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing